OMX Ventures

Constructive Bio is a biotechnology company focused on genome rewriting to unlock new possibilities in bioprocesses and biopharmaceuticals. The company transforms living cells into biofactories, producing sustainable materials and therapeutics. By harnessing advanced technologies, Constructive Bio creates virus-resistant organisms and biosynthesizes a range of enzymes, pharmaceuticals, and biomaterials. This innovative approach allows clients to reprogram genetic codes, enabling the creation of natural molecules that were previously inaccessible through conventional biology. Through its unique capabilities, Constructive Bio aims to lead the development of the next generation of sustainable solutions in the life sciences.

OverT Bio is a biotechnology company focused on developing cell therapies for cancer treatment. The company specializes in identifying and creating novel genetic modifications that empower immune cells to navigate and overcome the barriers posed by tumors. By enhancing the effectiveness and durability of immunotherapies, OverT Bio aims to advance the healthcare field's ability to identify and ultimately cure cancer.

Tagomics is a company focused on enhancing disease diagnosis through advanced multitopic profiling and epigenetic-based technologies. It specializes in the development of chemicals that facilitate the discovery of epigenetic biomarkers, providing a second layer of information to DNA beyond the traditional genetic code. This innovative approach enables the identification of biological markers that are sensitive to lifestyle, environmental factors, and disease states. By concentrating on early detection, particularly for colorectal and other common cancers, Tagomics aims to improve patient outcomes through more effective and cost-efficient diagnostic methods.

Freya Biosciences is a clinical-stage company focused on women's health, with operations in Copenhagen and Boston. It specializes in developing microbial immunotherapies aimed at addressing significant unmet medical needs across various conditions. The company utilizes a proprietary platform to engineer and manufacture live microbes, ensuring their safety and efficacy for human use. Through this innovative approach, Freya Biosciences seeks to create new treatment options for a range of diseases, striving to make a meaningful impact in the healthcare sector.

Aperiam Bio, founded in 2021 and based in Austin, Texas, specializes in the development of industrial and therapeutic proteins. The company collaborates with enzyme engineers and distributors to create stabilized, solubilized, and catalytically optimized proteins. Using advanced deep learning optimization and proprietary algorithms, Aperiam Bio identifies critical components of protein chemistry to discover novel gain-of-function mutations. This innovative approach enables the engineering of biological molecules for applications in agriculture and pharmaceuticals, allowing researchers to enhance the effectiveness and durability of proteins beyond their natural capabilities.

Lightcast Discovery Limited, founded in 2019 and based in Cambridge, United Kingdom, specializes in advancing drug discovery through its innovative microfluidic platform. This technology allows for precise control of thousands of droplets, enabling complex cell analysis and workflows without manual manipulation. By leveraging this platform, Lightcast collaborates with major pharmaceutical companies and leading academic institutions to develop new therapies and products. The company's focus is on pushing the boundaries of complex cell analysis, thereby facilitating the discovery of unique clinical approaches in the field of drug development.

Constructive Bio is a biotechnology company focused on genome rewriting to unlock new possibilities in bioprocesses and biopharmaceuticals. The company transforms living cells into biofactories, producing sustainable materials and therapeutics. By harnessing advanced technologies, Constructive Bio creates virus-resistant organisms and biosynthesizes a range of enzymes, pharmaceuticals, and biomaterials. This innovative approach allows clients to reprogram genetic codes, enabling the creation of natural molecules that were previously inaccessible through conventional biology. Through its unique capabilities, Constructive Bio aims to lead the development of the next generation of sustainable solutions in the life sciences.

Replay is a genome writing company focused on advancing genomic medicine by reprogramming biological systems through the synthesis and delivery of large DNA sequences. By innovating in the field of genetic engineering, Replay seeks to redefine the possibilities of genome manipulation and its applications in various medical and therapeutic contexts. Their work aims to facilitate breakthroughs in how genes can be utilized to treat diseases and enhance biological functions, positioning them at the forefront of the evolving landscape of genetic technology.

1859, Inc. is a biotechnology company established in 2019 and headquartered in San Diego, California. It specializes in the discovery and development of next-generation therapeutics, utilizing an artificial intelligence-powered drug discovery platform. This innovative platform combines combinatorial chemistry and pico-scale activity-based screening to generate extensive empirical data. By harnessing these advanced technologies, the company aims to expedite the discovery of novel small molecule therapeutics, offering valuable solutions to pharmaceutical companies in the healthcare industry.

Mythic Therapeutics is a biotechnology company dedicated to advancing cancer treatment through innovative antibody-drug conjugates (ADCs). The company specializes in a protein engineering approach that enhances the potency of ADCs while maintaining safety, allowing for more effective targeted therapies across various tumor types. By improving the uptake of these therapeutics in cancerous cells and minimizing payload release in healthy cells, Mythic Therapeutics aims to increase the efficacy of treatments without causing significant side effects or toxicity. This technology positions the company to make a meaningful impact in cancer care, enabling healthcare practitioners to better utilize ADCs for a wide array of patients.

Delix Therapeutics is a neuroscience company focused on harnessing the power of psychoplastogens—novel neuroplasticity-promoting therapeutics—to better treat mental health disorders at scale. The company was founded in 2019 and is headquartered in Boston, Massachusetts.

Glyphic Biotechnologies is a biotechnology company focused on developing an advanced protein sequencing platform that aims to enhance understanding of biological functions and diseases. Unlike DNA sequencing, which offers limited insights, this next-generation platform provides deeper knowledge through single-molecule, massively parallel sequencing. By improving binding affinity and consistency, Glyphic's technology supports the creation of personalized and precision cancer vaccines tailored to individual patients. The company's innovative approach enables scientists and researchers to develop novel therapeutics and diagnostics, ultimately advancing the comprehension of human biology and disease mechanisms.

Sestina Bio, LLC is a biotechnology company founded in 2020 and based in Delaware. The company focuses on developing a synthetic biology platform that engineers yeast and bacteria to produce chemicals and pharmaceuticals. Sestina Bio integrates innovative advances in synthetic biology, data sciences, and bio-analytical systems to create solutions addressing significant global challenges, such as sustainable food production, clothing, and health for an expanding population. Their offerings include tools for genome editing, single-cell biology, and machine learning, which enhance researchers' capabilities to engineer and exploit new biological functions.

Finch Therapeutics is a microbiome technology company focused on developing microbial therapies for patients with serious medical needs. The company utilizes donor-derived Full-Spectrum Microbiota and Rationally-Selected Microbiota platforms to create complete microbiome communities aimed at restoring functionality and addressing conditions caused by microbiome disruption. Finch offers oral microbiome treatments targeting recurrent C. difficile infections, chronic hepatitis B, inflammatory bowel disease, and gastrointestinal symptoms in children with autism. By employing machine learning algorithms, Finch analyzes clinical data to identify effective microbial combinations, thereby minimizing translational risks associated with drug development. Founded in 2017 and headquartered in Somerville, Massachusetts, Finch Therapeutics holds a significant portfolio of intellectual property, including over 70 patents related to microbiome therapeutics.

Delix Therapeutics is a neuroscience company focused on harnessing the power of psychoplastogens—novel neuroplasticity-promoting therapeutics—to better treat mental health disorders at scale. The company was founded in 2019 and is headquartered in Boston, Massachusetts.

Tara Biosystems provides predictive, in vitro human cardiac tissue models for use in drug discovery, safety assessment and translational medicine. Tara Biosystems offers a high-fidelity solution that is based on human stem cell-derived cardiac tissue matured to physiologically relevant adult-like levels and provides direct measures of cardiac functionality, including contractile force. The company is dedicated to pioneering predictive cardiac tissue models that enable the faster, safer, and more reliable development of new medicines.

Matterworks is a developer of an artificial intelligence platform focused on advancing the field of metabolomics within the life sciences. The company's technology enhances analytical capabilities, allowing scientific researchers to conduct faster and more comprehensive metabolomic screenings. By facilitating the discovery and engineering processes, Matterworks aims to accelerate scientific progress and support innovation in various biological applications.